» Articles » PMID: 33917412

Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2021 Apr 30
PMID 33917412
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

A novel, fast and sensitive enantioselective HPLC assay with a new core-shell isopropyl carbamate cyclofructan 6 (superficially porous particle, SPP) chiral column (LarihcShell-P, LSP) was developed and validated for the enantiomeric separation and quantification of verapamil (VER) in rat plasma. The polar organic mobile phase composed of acetonitrile/methanol/trifluoroacetic acid/triethylamine (98:2:0.05: 0.025, ) and a flow rate of 0.5 mL/min was applied. Fluorescence detection set at excitation/emission wavelengths 280/313 nm was used and the whole analysis process was within 3.5 min, which is 10-fold lower than the previous reported HPLC methods in the literature. Propranolol was selected as the internal standard. The S-(-)- and R-(+)-VER enantiomers with the IS were extracted from rat plasma by utilizing Waters Oasis HLB C18 solid phase extraction cartridges without interference from endogenous compounds. The developed assay was validated following the US-FDA guidelines over the concentration range of 1-450 ng/mL (r ≥ 0.997) for each enantiomer (plasma) and the lower limit of quantification was 1 ng/mL for both isomers. The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(-)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%. The developed approach was successfully applied to the stereoselective pharmacokinetic study of VER enantiomers after oral administration of 10 mg/kg racemic VER to Wistar rats. It was found that S-(-)-VER established higher C and area under the concentration-time curve (AUC) values than the R-(+)-enantiomer. The newly developed approach is the first chiral HPLC for the enantiomeric separation and quantification of verapamil utilizing a core-shell isopropyl carbamate cyclofructan 6 chiral column in rat plasma within 3.5 min after solid phase extraction (SPE).

Citing Articles

Development and Validation of a Novel UHPLC-MS/MS Method for the Quantification of Plinabulin in Plasma and Its Application in a Pharmacokinetic Study with Leukopenic Rats.

Niu X, Chen D, He W, Tang Y, Zhao J Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631067 PMC: 10459361. DOI: 10.3390/ph16081153.


A Liquid Chromatography Tandem Mass Spectrometry Method for the Simultaneous Estimation of the Dopamine Receptor Antagonist LE300 and Its N-methyl Metabolite in Plasma: Application to a Pharmacokinetic Study.

Hefnawy M, Attwa M, Alzamil A, El-Gendy M, El-Azab A, Bin Jardan Y Molecules. 2023; 28(4).

PMID: 36838539 PMC: 9964957. DOI: 10.3390/molecules28041553.

References
1.
Pagel P, Hettrick D, Lowe D, Gowrie P, Kersten J, Bosnjak Z . Cardiovascular effects of verapamil enantiomer combinations in conscious dogs. Eur J Pharmacol. 1998; 348(2-3):213-21. DOI: 10.1016/s0014-2999(98)00145-9. View

2.
Stagni G, Gillespie W . Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995; 667(2):349-54. DOI: 10.1016/0378-4347(95)00019-f. View

3.
Lankford S, Bai S . Determination of the stereochemical composition of the major metabolites of verapamil in dog urine with enantioselective liquid chromatographic techniques. J Chromatogr B Biomed Appl. 1995; 663(1):91-101. DOI: 10.1016/0378-4347(94)00409-x. View

4.
Zhang Y, Huo M, Zhou J, Xie S . PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010; 99(3):306-14. DOI: 10.1016/j.cmpb.2010.01.007. View

5.
Mateus F, Lepera J, Marques M, Boralli V, Lanchote V . Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007; 45(5):762-8. DOI: 10.1016/j.jpba.2007.09.021. View